newsfilter
← Latest News
Business Wire·

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

TransCode will use Signatera™ to identify MRD-positive patients eligible for enrollment Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc.